Diclofenac

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 28, 2024
Cream, Dysmenorrhea, Patient, History, Bacteria, G&A, Vaginal discharge, IND, Bayer, Human development, Investment, Diclofenac, NSAID, Menstruation, Research, Hormone, Bacterial vaginosis, P-value, Webcast, SAN, NIH, Trial of the century, Pleasure, Woman, Breast cancer, Safety, Pharmacokinetics, Food, Development, Menopause, Nonsteroidal anti-inflammatory drug, HR, ARPA, VVA, Tamoxifen, FDA, Attention, CRADA, Female, Dyspareunia, Ecosystem, NICHD, Bangladesh Technical Education Board

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Retrieved on: 
Wednesday, December 20, 2023
Food, Risk, Woman, Bloating, Diclofenac, FDA, Plasma, Dysmenorrhea, Nausea, Doctor of Philosophy, SAN, Pharmacokinetics, NSAID, Nonsteroidal anti-inflammatory drug, Menstruation, Observation, Safety, Vagina, Vomiting, Birth control

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.

Key Points: 
  • SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • The DARE-PDM1 Phase 1 study, DARE-PDM1-001, was a multi-center, randomized, placebo-controlled, double-blind, 3-arm parallel group study among approximately 42 healthy, premenopausal women with symptomatic primary dysmenorrhea.
  • The vaginal fluid PK results exhibited dose proportionality for the 1% and 3% diclofenac strengths of the DARE-PDM1 study treatment.
  • Pending the plasma PK data, the topline results of this Phase 1 study support continued clinical development of DARE-PDM1 for primary dysmenorrhea.

Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, CNS, CRADA, Brain, Research, Chronic pain, Food, Bupivacaine, Post-traumatic stress disorder, Osteoarthritis, US Foods, IND, Nose, Pain management, NCATS, Journal of Surgical Research, FDA, Marketing, Investigational New Drug, NIH, Trauma, MET, Pain, Patent, Central nervous system, Bangladesh Technical Education Board, OTC, Diclofenac, Pharmaceutical industry, 3D printing, Cryptocurrency

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments.
  • On September 27, 2023, Virpax announced results for two pre-clinical Probudur™ dose escalation studies.
  • On July 13, 2023, Virpax announced that it had filed a new provisional patent application with the USPTO entitled “Intranasal Delivery” related to its Envelta™ product candidate.
  • As of September 30, 2023, cash and cash equivalents were $12.2 million, compared to $19.0 million as of December 31, 2022.

Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders

Retrieved on: 
Thursday, November 2, 2023
Chronic pain, MDPI, Low back pain, MD, Diclofenac, Trigeminal neuralgia, Lidocaine, Skin, PALO, Biomedical Research, Clinical pharmaceutical scientist, Pain, Dermis, AAPS, Medical imaging

A set of studies assessed drug delivery from SP-103, ZTlido and control (Pennsaid®, 2% diclofenac) using open flow microperfusion.

Key Points: 
  • A set of studies assessed drug delivery from SP-103, ZTlido and control (Pennsaid®, 2% diclofenac) using open flow microperfusion.
  • Interstitial fluid from the dermis, subcutaneous adipose tissue, and muscle was continuously sampled to assess drug penetration in all tissue layers.
  • Current results of skin penetration studies for the first time had demonstrated uptake of lidocaine by muscle tissue via a passive diffusion through the skin.
  • We are very excited about these results supporting our clinical development plans,” said Dmitri Lissin, MD, Chief Medical Officer at Scilex.

Daré Bioscience Completes Previously Announced Equity Financing

Retrieved on: 
Tuesday, September 5, 2023
Cream, Vulvectomy, Diclofenac, Woman, Trial of the century, Douglas Pharmaceuticals, Pain, Human papillomavirus infection, SAN, HPV, FDA, Cervical intraepithelial neoplasia, Organon, Female, Birth control

The aggregate gross proceeds to Daré, before deducting offering expenses payable by Daré, were $7.0 million.

Key Points: 
  • The aggregate gross proceeds to Daré, before deducting offering expenses payable by Daré, were $7.0 million.
  • The closing occurred on September 1, 2023.
  • “This financing strengthened our balance sheet, providing cash to help us deliver on important portfolio milestones this year,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • A pharmaceutical approach could provide women with an important alternative to surgery to treat this condition.”
    Daré’s completed equity financing included minority participation by an investor affiliated with Douglas.

Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method

Retrieved on: 
Thursday, August 10, 2023
Surgery, Medical Devices, Infectious Diseases, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Patent, Central nervous system, Diclofenac, United States Patent and Trademark Office, CNS, Pain, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Post-traumatic stress disorder, OTC, Pain management, Gel, Hand, Osteoarthritis, IND, Skin, Pharmaceutical industry

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “NSAID Formulation and Method” related to its Epoladerm™product candidate.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “NSAID Formulation and Method” related to its Epoladerm™product candidate.
  • Epoladerm is an over-the counter (OTC) diclofenac topical spray film that Virpax is developing for pain associated with Osteoarthritis.
  • Epoladerm is designed to be less messy than gels or creams which are applied by hand and which may contaminate public water supplies with the active pharmaceutical ingredients the gels or creams carry.
  • “We have completed our IND enabling trials for Epoladerm and are pleased to file this patent application that we expect will expand our protection and increase the patent life for this novel formulation,” stated Anthony P. Mack , Chairman and CEO of Virpax.

Global Analgesics Market Report 2023: Sector is Expected to Reach $67.55 Billion by 2028 at a CAGR of 4.6% - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 1, 2023
Health, Pharmaceutical, Infection, Liver, Analgesic, Drug development, Prevalence, Diabetes, Drug overdose, Arthritis, Perception, European Medicines Agency, COVID-19, Stroke, Anesthetic, Cancer, Intelligence, Brain, Research, Kidney, Pain, Intravenous therapy, Administration, Incidence, Opioid, Haleon, Paracetamol, Nonsteroidal anti-inflammatory drug, Pain management, Oral, Drug, Growth, Ibuprofen, Chronic pain, Pharmaceutical industry, Diclofenac

The global analgesics market value is projected to grow at a CAGR of 4.6%, during the forecast period of 2023-2028.

Key Points: 
  • The global analgesics market value is projected to grow at a CAGR of 4.6%, during the forecast period of 2023-2028.
  • In 2022, the global analgesics market was valued at US$51.63 billion, and is probable to reach US$67.55 billion by 2028.
  • There are several different types of analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, and local anesthetics.
  • Trends: A major trend gaining pace in analgesics market is use of artificial intelligence in analgesics.

Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook

Retrieved on: 
Tuesday, May 9, 2023
Spectrum Pharmaceuticals, GAAP, EBITDA, Acquisition, Growth, Assertio Therapeutics, EPS, G-CSF, Video game, Pharmaceutical industry, Cryptocurrency, Bank, Security (finance), Diclofenac, Clobazam, Indometacin

LAKE FOREST, Ill., May 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Indocin sales increased 42%, primarily due to the transition of volumes to more profitable commercial channels implemented in October 2022.
  • Sympazan prescriptions achieved a new record in the quarter, following its prior record in the third quarter 2022.
  • GAAP net loss of $3.5 million, compared to GAAP net income of $9.1 million in the prior year quarter.
  • At March 31, 2023, cash and cash equivalents was $68.6 million and outstanding principal amount of convertible debt was $40 million.

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

Retrieved on: 
Wednesday, February 22, 2023
Safety, American College, Adolescence, Dysmenorrhea, Pain, Diclofenac, Peptic ulcer disease, Risk, Vomiting, FDA, Menstruation, Observation, Nonsteroidal anti-inflammatory drug, Primary, Plasma, SAN, Nausea, Vagina, Myometrium, Bloating, Student, Woman, Food, Abdomen, NSAID, USD, Current Problems in Pediatric and Adolescent Health Care, Pharmaceutical industry, Birth control

Primary dysmenorrhea is defined as painful menstruation in women with normal pelvic anatomy, typically described as cramping pain in the lower abdomen before or during the menstrual period.

Key Points: 
  • Primary dysmenorrhea is defined as painful menstruation in women with normal pelvic anatomy, typically described as cramping pain in the lower abdomen before or during the menstrual period.
  • Oral NSAIDs, such as diclofenac, are often recommended for temporary relief from the painful symptoms of primary dysmenorrhea².
  • “The potential benefits of DARE-PDM1 as a potential treatment for the millions of women suffering from primary dysmenorrhea are driven by its unique target product profile,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • “The most common interventions for primary dysmenorrhea include oral NSAIDs and hormonal contraceptives which often can produce undesirable side effects.

Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%

Retrieved on: 
Tuesday, January 3, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, OSD, Pain, NSAID, Diclofenac, Patient, Ophthalmology, Rheumatology, IBSA, Bruise, NDC, Endocrinology, Pharmaceutical industry, Fine chemical

Yaral Pharma Inc. , the US generics subsidiary of IBSA , a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland today announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma’s Flector® (diclofenac epolamine) topical system.

Key Points: 
  • Yaral Pharma Inc. , the US generics subsidiary of IBSA , a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland today announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma’s Flector® (diclofenac epolamine) topical system.
  • Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
  • “Like Flector, Yaral Pharma’s diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment backed by more than 30 years of clinical experience.
  • We are pleased to offer patients an accessible and affordable product that offers targeted topical pain relief and look forward to expanding our product line across a range of therapeutic areas in the months ahead.”
    Yaral Pharma’s diclofenac epolamine topical system 1.3% patch (NDC 82347-0405-5) is currently available to order.